Ten-year estimated risk of bone fracture in women with differentiated thyroid cancer under TSH-suppressive levo-thyroxine therapy.

Ten-year estimated risk of bone fracture in women with differentiated thyroid cancer under TSH-suppressive levo-thyroxine therapy. Endokrynol Pol. 2016 Jul 8; Authors: Vera L, Gay S, Campomenosi C, Paolino S, Pera G, Monti E, Mortara L, Seriolo B, Giusti M Abstract BACKGROUND: After thyroidectomy and radioiodine therapy, patients with differentiated thyroid cancer (DTC) are indefinitely treated with levo-thyroxine (L-T4). Osteoporosis is a debated consequence of hyperthyroxinemia. The aim of this study was to evaluate bone mineral density (BMD) and a fracture risk assessed by FRAX in a cohort of DTC women. METHODS: Seventy-four women with DTC (56.5±9.9 years) treated at the age of 51.9±12.0 years were studied. Baseline BMD and FRAX were evaluated after 3.0 years (median). A 2nd BMD and FRAX evaluation was performed 5.5years (median) after baseline evaluation. A cohort of 120 euthyroid women, matched for age, BMI and menopausal status, were evaluated as controls. RESULTS: Levo-T4 dosages were 813.6±208.8 µg/week and 782.1±184.4 µg/week at the baseline and 2nd evaluation, respectively. The risks of major osteoporotic fracture (MOF) and hip fracture (HF) were similar in DTC patients and controls. In DTC women, significant changes in FRAX were found, with a higher increase in the probability of HF than of MOF. A similar change was found in controls. A significant inverse correlation (P. PMID: 27387240 [Pu...
Source: Endokrynologia Polska - Category: Endocrinology Authors: Tags: Endokrynol Pol Source Type: research